| |
|
The Fund was the lead investor in a Series C financing for Ambrx, a US Lifesciences
company that has developed a patent-protected technology for optimising protein-based drugs. Annual
sales of protein therapeutics are expected to reach approximately US$60 billion by 2010, but unmodified
proteins are frequently badly adapted for use, often being broken down too rapidly in the body. Ambrx's
world-class technology allows proteins to be substantially improved in very controllable and predictable ways,
thereby increasing their commercial potential.
|
| |
|
Serentis is a new UK Lifesciences company being established by the Fund along with 2 other investors, in
collaboration with a management team taken from another successful Lifesciences company. Serentis' strategy is to
identify opportunities to develop new products based on drugs that are already used for other indications. This is
a strategy that Serentis' management team have successfully pursued together in the past.
|
| |
|
Pharmakodex Limited is a UK based speciality pharmaceuticals company. The company was spun out from Vectura Group
plc and Unilever plc in May 2006 to exploit proprietary formulation and delivery technology from both parents. The
company's product portfolio focuses on improving existing drugs to provide faster acting, more convenient and more
effective products, protected by strong intellectual property.
|
| |
|
CancerPartners is a new UK company set up in collaboration with the former head of the World Health Organisation's
Cancer Program and the former CEO of UK cancer operations for one of the US's largest for-profit healthcare groups. The
aim of the company is to introduce internationally-recognised models of "distributed" cancer care into the UK for the
first time.
|
| |
|
By the Bridge is a UK-based company that provides highly-trained foster parents for children with particularly
challenging needs, many of whom might otherwise require expensive, and often counter-productive, residential care. With
a strong emphasis on quality of service, By the Bridge has consistently received the highest score from government
inspectors of all private sector foster care companies in the UK.
|
|
Ambit Biosciences is a San Diego-based company engaged in the discovery and development of small-molecule kinase
inhibitors for the treatment of cancer. Ambit is combining the power of its KinomeScan kinase profiling technology
with an innovative licensing strategy and a history of kinase expertise to discover, optimise and advance a sustainable
pipeline which already includes several drug candidates in clinical and pre-clinical development.
|
| |
